is hims glp 1 legit Inc Full Range of FDA-Approved GLP-1s

While these medications were originally developed for type 2 diabetes and later gained widespread use for obesity management, researchers are now examining whether they may also improve pain, stiffness, and mobility

Peripheral arterial disease (PAD) is a clinical manifestation of atherosclerotic disease, typically affecting the abdominal aorta, iliac arteries, and lower limbs.1 This condition is associated with a higher risk of major adverse cardiovascular events (MACE) and major adverse limb events (MALE), and is a strong predictor of both all-cause and cardiovascular mortalities.2 Additionally, hospitalizations due to PAD have led to a substantial economic burden on health care systems.3 In addition to their glucose-lowering effects, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with weight loss and have multiple favorable metabolic and anti-inflammatory effects.4 Due to their cardio- and nephro-protective properties, GLP-1RAs are recommended as first-line antidiabetic therapies for patients at high cardiovascular risk.5 Moreover, GLP-1RAs may improve arterial stiffness and provide systemic microcirculatory benefits in the peripheral vascular system

Studies have shown that these medications are seeing slightly more weight loss (15-18% of total body weight) compared to Qsymia

Liraglutide (800 g/kg

Mixed experiences in customer support but fulfillment delays reported

The use of diabetes and weight-loss medications like Ozempic or Wegovy called GLP-1 drugs has exploded in recent years, with 12% of U.S